First-Trimester Genetic Ultrasound Report

Maternal-Fetal Medicine — 11–14 Week Sonographic Risk Assessment

Report ID: MAA-PUG-7C5B91
Generated: May 12, 2026
Analysis: AI-Powered Image Interpretation

Patient Profile

Maternal age:
40 years
Gestational age:
13 weeks 1 day (CRL 71 mm)
Pregnancy:
G3P0 — singleton, IVF (own oocyte)
Indication for scan:
Advanced maternal age, prior NIPT showing low-risk T21/18/13 — additional sonographic risk markers requested
Examiner credentials:
FMF-certified sonographer, equipment with appropriate calibration

Summary Overview

Standardized first-trimester ultrasound assessing all four FMF aneuploidy markers (NT, nasal bone, ductus venosus a-wave, tricuspid regurgitation). 4 markers evaluated; 1 mildly abnormal (NT 2.7 mm, just above the 95th percentile for CRL). Biophysical anatomy survey within normal limits for gestational age.

4
Markers Assessed
1
Mildly Abnormal
3
Normal

Integrated Risk Modifiers

Background risk (T21):
1:80 at age 40 (a priori) [Snijders RJ, Lancet 1999]
Post-NIPT risk (T21):
< 1:10,000 (NIPT result reported low-risk; PPV ≥99%) [ACOG 226, 2020]
Sonographic adjustment:
NT 2.7 mm (~95th–97th percentile) — minor likelihood ratio increase
Final integrated risk:
Remains low for the major aneuploidies; structural follow-up recommended for non-chromosomal causes of NT elevation

Detailed Marker Analysis

Nuchal Translucency (NT)Borderline
Measurement
2.7 mm
95th pctile (CRL 71mm)
~2.6 mm
≥ 3.5 mm threshold
Not met
NT is just above the 95th percentile for CRL but well below the 3.5 mm "marked" threshold. With a low-risk NIPT result already in hand, the residual likelihood ratio for major aneuploidy is small. However, NT in the upper range warrants structural follow-up — increased NT with normal karyotype carries a small but recognized association with congenital heart defects, lymphatic malformations, skeletal dysplasias, and rare genetic syndromes [Souka AP, Am J Obstet Gynecol 2005; Bilardo CM, Ultrasound Obstet Gynecol 2007].
Nasal BonePresent
Status
Visible / Ossified
T21 association
Absent in ~60%
Result interpretation
Reassuring
Nasal bone is present and well visualized in the midsagittal plane. Absent or hypoplastic nasal bone is a strong sonographic marker for trisomy 21 [Cicero S, Ultrasound Obstet Gynecol 2003]. Visualization is reassuring.
Ductus Venosus a-waveAntegrade
a-wave
Antegrade (positive)
Reversed/absent
Not present
Result interpretation
Normal
Antegrade a-wave during atrial contraction. Reversed or absent a-wave is associated with aneuploidy and cardiac defects [Maiz N, Fetal Diagn Ther 2010].
Tricuspid FlowNo Regurgitation
Status
No regurgitation
Significance
Reassuring
Result interpretation
Normal
No tricuspid regurgitation detected. TR is associated with aneuploidy and cardiac defects when present at 11–13+6 weeks [Falcon O, Ultrasound Obstet Gynecol 2006].

Structural Anatomy Survey (limited at this gestation)

  • Skull: normal contour, choroid plexuses symmetric, falx midline
  • Spine: ossified, no obvious dysraphism
  • Abdominal wall: intact, physiologic midgut herniation has resolved
  • Cardiac four-chamber view: identified, axis normal
  • Stomach, bladder: visualized
  • Limbs: four limbs identified, segments visualized

Detailed cardiac and structural assessment will be more sensitive at the second-trimester anatomy scan (18–22 weeks).

Risk Interpretation

  • Major aneuploidy (T21/18/13)Low (post-NIPT)
    NIPT > 99% PPV for these conditions in high-risk maternal age; isolated borderline NT with no additional markers does not meaningfully alter this.
  • Congenital heart defect (CHD)Modest excess
    NT in upper range with normal karyotype carries roughly 2–3% absolute CHD risk vs ~0.7% baseline [Souka AP 2005]. Detailed fetal echocardiogram is recommended.
  • Other genetic syndromes (e.g. Noonan, skeletal dysplasias)Low
    Most NT > 95th percentile cases with normal karyotype and normal anatomy proceed uneventfully [Bilardo CM 2007]. Optional expanded molecular testing (e.g., Noonan panel) may be discussed.

Analytical Summary & Recommendations

Clinical pattern

NIPT-low-risk pregnancy with isolated borderline NT (2.7 mm) and otherwise reassuring first-trimester aneuploidy markers and structural survey. Aneuploidy risk is robustly low; the relevant residual question is non-chromosomal etiology of the borderline NT.

Recommended next steps

  • Detailed fetal anatomy scan at 18–22 weeks with particular attention to cardiac structures
  • Fetal echocardiography at ~20–22 weeks (specialist) given upper-range NT
  • Discuss optional expanded molecular testing (e.g., chromosomal microarray, Noonan-spectrum gene panel) — optional given low overall residual risk
  • Review with maternal-fetal-medicine specialist — joint counseling appropriate given maternal age
  • Routine prenatal care otherwise; no immediate intervention required

Key Questions for Your Physician

  • Given my normal NIPT, how much should the borderline NT change my plans?
  • Should I have a specialist fetal echocardiogram, and when?
  • Is expanded genetic testing (microarray, gene panels) recommended in my case?
  • What specific structures will be examined at the anatomy scan?
  • What signs would prompt earlier follow-up imaging?

What This Means for You

Your first-trimester ultrasound is largely reassuring. Three of the four "early-pregnancy markers" used to refine genetic risk look completely normal, and your previously low-risk NIPT remains the strongest reassurance for Down syndrome and the other major chromosomal conditions.

There is one finding worth following up: the back-of-neck measurement (NT) is just above the typical range (2.7 mm versus a 95th-percentile cutoff of about 2.6 mm at this fetal size). On its own, with everything else normal and a low-risk NIPT, this is not a major concern for chromosomal conditions. However, slightly larger NT measurements are associated with a modestly higher chance of congenital heart defects — for that reason, a specialist fetal heart ultrasound at around 20–22 weeks is recommended.

The full 20-week anatomy scan remains the most informative next step. Your prenatal team will help you decide whether any additional genetic testing would be useful in your case.

Analysis Confidence 86%

High confidence in marker interpretation given FMF-standard examination quality. The borderline NT carries inherent interpretive uncertainty — clinical context (maternal age, low-risk NIPT) and downstream imaging (anatomy scan, fetal echo) refine the picture.

References

  1. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Am J Obstet Gynecol 2011;204(5):359–369.
  2. Souka AP, Von Kaisenberg CS, Hyett JA, et al. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005;192(4):1005–21.
  3. Bilardo CM, Müller MA, Pajkrt E, et al. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 2007;30(1):11–8.
  4. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides KH. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation. Lancet 2001;358:1665–7.
  5. Maiz N, Wright D, Ferreira AF, Syngelaki A, Nicolaides KH. Ductus venosus flow at 11+0 to 13+6 weeks for the prediction of outcome in twin pregnancies. Fetal Diagn Ther 2010;28:104–11.
  6. Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free β-hCG and PAPP-A at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol 2006;27(2):151–5.
  7. ACOG Practice Bulletin 226: Screening for Fetal Chromosomal Abnormalities. Obstet Gynecol 2020;136(4):e48–e69.